Published in Rev Diabet Stud on May 10, 2004
B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity (2000) 15.44
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002) 8.84
Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu Rev Physiol (1995) 7.16
Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med (1987) 5.48
Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature (1992) 5.47
Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature (1993) 5.47
Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science (1992) 5.36
Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature (1993) 5.10
Insulin-dependent diabetes mellitus. Cell (1996) 5.06
Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol (2001) 4.99
In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med (1985) 4.65
Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science (1992) 4.53
TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med (2003) 4.40
Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med (2001) 3.85
Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A (1994) 3.77
Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library. Nat Med (1999) 3.45
Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet (2001) 3.26
Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med (1994) 3.24
Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med (1995) 3.18
Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci U S A (1991) 2.72
Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest (1993) 2.64
Autoimmune type 1 diabetes: resolved and unresolved issues. J Clin Invest (2001) 2.35
Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci U S A (1996) 2.21
CD28 ligation in T-cell activation: evidence for two signal transduction pathways. Blood (1990) 2.21
Vascular addressins are induced on islet vessels during insulitis in nonobese diabetic mice and are involved in lymphoid cell binding to islet endothelium. J Clin Invest (1993) 2.10
Insulin-specific T cells are a predominant component of islet infiltrates in pre-diabetic NOD mice. Eur J Immunol (1994) 2.07
Detection of GAD65-specific T-cells by major histocompatibility complex class II tetramers in type 1 diabetic patients and at-risk subjects. Diabetes (2002) 2.01
Pancreatic islet-cell antibodies in diabetes mellitus correlated with the duration and type of diabetes, coexistent autoimmune disease, and HLA type. Diabetes (1977) 1.88
Macrophages, T cell receptor usage, and endothelial cell activation in the pancreas at the onset of insulin-dependent diabetes mellitus. J Clin Invest (1992) 1.80
Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes (1992) 1.74
Response of peripheral-blood mononuclear cells to glutamate decarboxylase in insulin-dependent diabetes. Lancet (1992) 1.73
IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A (1996) 1.71
A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin. J Clin Invest (2001) 1.70
Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. Lancet (1993) 1.68
Cytotoxic T cells specific for glutamic acid decarboxylase in autoimmune diabetes. J Exp Med (1995) 1.67
CD43, a molecule defective in Wiskott-Aldrich syndrome, binds ICAM-1. Nature (1991) 1.60
A prospective study of the development of diabetes in relatives of patients with insulin-dependent diabetes. N Engl J Med (1990) 1.53
Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes (1990) 1.51
Identification of a second transmembrane protein tyrosine phosphatase, IA-2beta, as an autoantigen in insulin-dependent diabetes mellitus: precursor of the 37-kDa tryptic fragment. Proc Natl Acad Sci U S A (1996) 1.51
Administration of silica particles or anti-Lyt2 antibody prevents beta-cell destruction in NOD mice given cyclophosphamide. Diabetes (1988) 1.43
Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta, and prostaglandin-E. Am J Pathol (1995) 1.32
Identification of a beta-cell-specific HLA class I restricted epitope in type 1 diabetes. Diabetes (2003) 1.30
Genes encoding tumor necrosis factor alpha and granzyme A are expressed during development of autoimmune diabetes. Proc Natl Acad Sci U S A (1990) 1.28
Anti-peptide autoantibodies and fatal anaphylaxis in NOD mice in response to insulin self-peptides B:9-23 and B:13-23. J Clin Invest (2002) 1.26
Peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes. J Immunol (2003) 1.25
Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various beta-cell antigens. Diabetes (1997) 1.24
Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes (2002) 1.23
Peripheral blood mononuclear cells of insulin-dependent diabetic patients respond to multiple islet cell proteins. J Immunol (1996) 1.18
Identification and modulation of a naturally processed T cell epitope from the diabetes-associated autoantigen human glutamic acid decarboxylase 65 (hGAD65). Proc Natl Acad Sci U S A (2001) 1.17
Twin-to-twin pancreas transplantation: reversal and reenactment of the pathogenesis of type I diabetes. Trans Assoc Am Physicians (1984) 1.15
Identification of naturally processed T cell epitopes from glutamic acid decarboxylase presented in the context of HLA-DR alleles by T lymphocytes of recent onset IDDM patients. J Clin Invest (1997) 1.14
The pathogenesis of adoptive murine autoimmune diabetes requires an interaction between alpha 4-integrins and vascular cell adhesion molecule-1. J Clin Invest (1994) 1.11
T-cell reactivity to beta-cell membrane antigens associated with beta-cell destruction in IDDM. Diabetes (1995) 1.05
Are insulin autoantibodies markers for insulin-dependent diabetes mellitus? Diabetes (1986) 1.01
Cellular immunity to human insulin in individuals at high risk for the development of type I diabetes mellitus. J Autoimmun (1990) 1.00
IA-2-autoantibodies complement GAD65-autoantibodies in new-onset IDDM patients and help predict impending diabetes in their siblings. The Belgian Diabetes Registry. Diabetologia (1997) 1.00
Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4. Cancer Res (1999) 1.00
Islet cell cytoplasmic autoantibody reactivity to glutamate decarboxylase in insulin-dependent diabetes. J Clin Invest (1993) 0.97
Type 1 diabetes: molecular, cellular and clinical immunology. Adv Exp Med Biol (2004) 0.96
Tolerogenic strategies to halt or prevent type 1 diabetes. Nat Immunol (2001) 0.96
High levels of antigen-specific islet antibodies predict future beta-cell failure in patients with onset of diabetes in adult age. J Clin Endocrinol Metab (2001) 0.94
Definition of multiple ICA512/phogrin autoantibody epitopes and detection of intramolecular epitope spreading in relatives of patients with type 1 diabetes. Diabetes (1998) 0.94
Treatment of NOD diabetes with a novel peptide of the hsp60 molecule induces Th2-type antibodies. J Autoimmun (1997) 0.94
Immunotherapy of insulin-dependent diabetes mellitus. Curr Opin Immunol (2002) 0.92
Treatment of autoimmune diabetes and insulitis in NOD mice with heat shock protein 60 peptide p277. Diabetes (1995) 0.90
Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial. Diabetologia (1998) 0.89
Autoantibodies against GAD65 rather than GAD67 precede the onset of type 1 diabetes. Autoimmunity (1994) 0.87
Anti-CD43 monoclonal antibody L11 blocks migration of T cells to inflamed pancreatic islets and prevents development of diabetes in nonobese diabetic mice. J Immunol (1999) 0.87
Karlsburg Type I diabetes risk study of a general population: frequencies and interactions of the four major Type I diabetes-associated autoantibodies studied in 9419 schoolchildren. Diabetologia (1999) 0.87
Islet T cells secreting IFN-gamma in NOD mouse diabetes: arrest by p277 peptide treatment. J Autoimmun (1998) 0.86
Prevention of cyclophosphamide-induced and spontaneous diabetes in NOD/Shi/Kbe mice by anti-MHC class I Kd monoclonal antibody. Diabetes (1991) 0.86
Identification and characterization of glima 38, a glycosylated islet cell membrane antigen, which together with GAD65 and IA2 marks the early phases of autoimmune response in type 1 diabetes. J Clin Invest (1996) 0.85
Cytokines and direct cell contact in synovitis: relevance to therapeutic intervention. Arthritis Res (1999) 0.84
Nondepleting anti-CD4 has an immediate action on diabetogenic effector cells, halting their destruction of pancreatic beta cells. J Immunol (2000) 0.84
Nondepleting anti-CD4 monoclonal antibody prevents diabetes and blocks induction of insulin autoantibodies following insulin peptide B:9-23 immunization in the NOD mouse. J Autoimmun (2003) 0.83
Leukocytes infiltrating the pancreatic islets of nonobese diabetic mice are transformed into inactive exiles by combinational anti-cell adhesion therapy. J Leukoc Biol (2001) 0.82
An altered self-peptide with superagonist activity blocks a CD8-mediated mouse model of type 1 diabetes. J Immunol (2004) 0.82
Stem cell transplantation for severe autoimmune disorders, with special reference to rheumatic diseases. J Rheumatol Suppl (1997) 0.81
Immunization of diabetes-prone or non-diabetes-prone mice with GAD65 does not induce diabetes or islet cell pathology. J Autoimmun (1998) 0.81
The relationship between peripheral T cell reactivity to insulin, clinical remissions and cytokine production in type 1 (insulin-dependent) diabetes mellitus. J Clin Endocrinol Metab (1999) 0.81
In vivo administration of anti-murine CD3 monoclonal antibody induces selective, long-term anergy in CD8+ T cells. Transplantation (1996) 0.80
Clinical trials for the prevention of type 1 diabetes. Adv Exp Med Biol (2004) 0.76
Genetics of type 1 insulin-dependent diabetes mellitus. Horm Res (1997) 0.76
Apoptosis in autoimmune diabetes: the fate of beta-cells in the cleft between life and death. Rev Diabet Stud (2006) 0.76